Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?

Medicine and Dentistry

• Targeted Therapy 100%
• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor 100%
• Tyrosine-Kinase Inhibitor 60%
• Combination Therapy 50%
• Therapeutic Procedure 20%
• Cancer Therapy 20%
• Mutant 20%
• Lung Cancer 10%
• Patient 10%
• Chemoradiotherapy 10%
• Patient Population 10%
• Toxicity 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Protein Tyrosine Kinase Inhibitor 85%
• Toxicity 14%
• Chemotherapy 14%
• Lung Cancer 14%
• Chemoradiation Therapy 14%
• Randomized Clinical Trial 14%
• Clinical Trial Results 14%